Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 6/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.35 |
| ▸ | ICMT | O60725 | 1/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | RARA | P10276 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | RARG | P13631 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19940307 | 0.90 | GCGR (0.43) | GCGRADRB3DGAT1 | |
| SCHEMBL19922897 | 0.89 | GCGR (0.55) | GCGRADRB3P2RY14 | |
| SCHEMBL19940306 | 0.87 | GCGR (0.63) | GCGR | |
| SCHEMBL19940309 | 0.83 | GCGR (0.52) | GCGR | |
| SCHEMBL19940302 | 0.82 | GCGR (0.45) | GCGRICMTRARARARB | |
| SCHEMBL19923020 | 0.81 | GCGR (0.54) | GCGRADRB3 | |
| SCHEMBL19922880 | 0.78 | GCGR (0.73) | GCGR | |
| SCHEMBL19922909 | 0.76 | GCGR (0.61) | GCGR | |
| SCHEMBL19922788 | 0.76 | GCGR (0.61) | GCGRP2RY14 | |
| SCHEMBL19922851 | 0.76 | GCGR (0.72) | GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251864-B2 | Indole derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-09 | — | — | US | disclosed |
| US-20180064686-A1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
| US-20180064686-A1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251864-B2 | Indole derivatives useful as glucagon receptor antagonists | GPR119, GIPR, GLP1R | GCGR 4/4885ADRB3 70/4885P2RY14 1249/4885 |
| US-20180064686-A1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GIPR, GLP1R | GCGR 4/4885ADRB3 70/4885P2RY14 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.